In March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2,
presented with fever and significant inflammation about a month after exposure to the virus.
Some children were sick enough to require care in the intensive care unit for what came to be
known as Multisystem Inflammatory Syndrome-Children (MIS-C).The clinical presentation shared
many features with Kawasaki disease (KD), a self-limited inflammation that can cause
ballooning of the arteries of the heart. Thus, physicians reached for many of the therapies
used to treat children with KD. Despite the surge of COVID-19 cases and children continuing
to present with MIS-C, there are no data that guide the choice of therapy. Thus, the
investigators have designed a study to determine which combination of therapies is most
effective in helping children with MIS-C recover quickly.